Bayer: AlphaValue downgrades Buy rating to Add
(CercleFinance.com) - AlphaValue on Wednesday downgraded its rating on Bayer shares from "buy" to "add", pointing to the increasingly exorbitant price tag associated with the Monsanto acquisition.
In its comments, the independent broker warns that the risks associated with the glyphosate issue are not about to disappear, with 2037 appearing to be the year in which all litigation with individuals will have been settled.
However, AlphaValue also points out that some forms of cancer take time to develop.
For the time being though, the Parisian firm prefers to take into account the new 3.8 billion euro provision that the German group announced last week.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.